CDK4 and small cell lung carcinoma: Finally, although there is a theoretical concern that trilaciclib may antagonise the intended antitumor efficacy of chemotherapy in CDK4/6‐dependent tumours, trilaciclib had no impact on the efficacy of chemotherapy in the SCLC studies, or in preclinical models of CDK4/6‐dependent and ‐independent tumours.25, 29, 30, 31, 32, 54